Tarenflurbil

Identification

Name
Tarenflurbil
Accession Number
DB05289  (DB12936)
Type
Small Molecule
Groups
Investigational
Description

Tarenflurbil is an investigational drug that was studied in patients with mild Alzheimer's disease. It is a selective amyloid lowering agent (SALA) that reduces levels of the toxic peptide amyloid beta 42 (Aβ42) in cultured human cells and in animal models. Aβ42 is the primary initiator of neurotoxicity and amyloid plaque development in the brains of Alzheimer's disease patients. In June 2008 development of the drug for Alzheimer's disease was discontinued. Tarenflurbil has also been used in trials studying the treatment of Prostate Cancer.

Structure
Thumb
Synonyms
  • (−)-(2R)-2-(2-fluorobiphenyl-4-yl)propanoic acid
  • (2R)-2-(2-fluorobiphenyl-4-yl)propanoic acid
  • (R)-2-fluoro-α-methyl(1,1'-biphenyl)-4-acetic acid
  • (R)-flurbiprofen
External IDs
E-7869 / MPC-7869
International/Other Brands
Flurizan
Categories
UNII
501W00OOWA
CAS number
51543-40-9
Weight
Average: 244.2609
Monoisotopic: 244.089957865
Chemical Formula
C15H13FO2
InChI Key
SYTBZMRGLBWNTM-SNVBAGLBSA-N
InChI
InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)/t10-/m1/s1
IUPAC Name
(2R)-2-(3-fluoro-4-phenylphenyl)propanoic acid
SMILES
C[C@@H](C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1

Pharmacology

Indication

Investigated for use/treatment in alzheimer's disease and prostate cancer.

Pharmacodynamics
Not Available
Mechanism of action

MPC-7869 is not an inhibitor of cyclooxygenase enzymes (COX-1 and COX-2). The compound modulates the signal transduction and transcription activation pathways associated with nuclear factor kappaB (NFkappaB), a principle transcription factor in the expression of many molecules involved in cell growth, cell death and inflammation. In addition, MPC-7869 has recently been shown to modulate gamma-secretase and selectively lower levels of Abeta42 peptide in vitro and in vivo, and to reduce amyloid pathology in the brain. MPC-7869 has an excellent safety profile and is very potent in animal models of cancer and Alzheimer's disease. In transgenic mouse studies, MPC-7869 reduced brain amyloid levels and prevented memory loss.

TargetActionsOrganism
UNF-kappa-B essential modulatorNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with (4R)-limonene.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with 5-androstenedione.Experimental, Illicit
AbciximabTarenflurbil may increase the anticoagulant activities of Abciximab.Approved
AcebutololTarenflurbil may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolTarenflurbil may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Tarenflurbil.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Alendronic acid.Approved
AliskirenTarenflurbil may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Alminoprofen.Experimental
AlprenololTarenflurbil may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Tarenflurbil.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Amcinonide.Approved
AmilorideTarenflurbil may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Aminosalicylic Acid.Approved
AncrodTarenflurbil may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Antipyrine.Approved, Investigational
Antithrombin III humanTarenflurbil may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Antrafenine.Approved
ApixabanTarenflurbil may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Apocynin.Investigational
ApramycinTarenflurbil may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Apremilast.Approved, Investigational
ArbekacinTarenflurbil may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinTarenflurbil may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanTarenflurbil may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololTarenflurbil may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapineTarenflurbil may decrease the antihypertensive activities of Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Atamestane.Investigational
AtenololTarenflurbil may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Tarenflurbil.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tarenflurbil.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Tarenflurbil.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Balsalazide.Approved, Investigational
BecaplerminTarenflurbil may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BefunololTarenflurbil may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinTarenflurbil may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tarenflurbil.Approved
BenorilateThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Tarenflurbil.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Tarenflurbil.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Tarenflurbil.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Betamethasone.Approved, Vet Approved
BetaxololTarenflurbil may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Tarenflurbil.Approved, Investigational
BevantololTarenflurbil may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Tarenflurbil.Approved, Investigational
BisoprololTarenflurbil may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinTarenflurbil may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololTarenflurbil may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Bucillamine.Investigational
BucindololTarenflurbil may decrease the antihypertensive activities of Bucindolol.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Bufexamac.Approved, Experimental
BufuralolTarenflurbil may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Tarenflurbil.Approved
BupranololTarenflurbil may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Tarenflurbil.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Tarenflurbil.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Candoxatril.Experimental
CapsaicinThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Tarenflurbil.Approved
CarprofenThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololTarenflurbil may decrease the antihypertensive activities of Carteolol.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Tarenflurbil.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Celecoxib.Approved, Investigational
CeliprololTarenflurbil may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinTarenflurbil may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Tarenflurbil.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tarenflurbil.Approved, Vet Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Tarenflurbil.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Tarenflurbil resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Cilazapril.Approved
CimicoxibThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Cimicoxib.Investigational
CinoxacinTarenflurbil may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CisplatinThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Cisplatin.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Tarenflurbil.Vet Approved
CloranololTarenflurbil may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Tarenflurbil resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Tarenflurbil resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Curcumin.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Tarenflurbil.Experimental
Dabigatran etexilateTarenflurbil may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinTarenflurbil may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidTarenflurbil may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanTarenflurbil may increase the anticoagulant activities of Darexaban.Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Delapril.Investigational
DesipramineTarenflurbil may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinTarenflurbil may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Tarenflurbil.Approved, Investigational
DextranTarenflurbil may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinTarenflurbil may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Dibotermin alfa.Approved, Investigational
DicoumarolTarenflurbil may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Tarenflurbil.Approved
DihydrostreptomycinTarenflurbil may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Tarenflurbil.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Tarenflurbil.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Tarenflurbil.Approved
DrospirenoneTarenflurbil may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Tarenflurbil is combined with E-6201.Investigational
Edetic AcidTarenflurbil may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanTarenflurbil may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Enalaprilat.Approved
EnoxacinTarenflurbil may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinTarenflurbil may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Tarenflurbil.Experimental
EpanololTarenflurbil may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Epirizole.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Tarenflurbil.Experimental
EplerenoneTarenflurbil may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Tarenflurbil.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tarenflurbil.Approved
EquileninThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Equilin.Approved
EsatenololTarenflurbil may decrease the antihypertensive activities of Esatenolol.Experimental
EsmololTarenflurbil may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Tarenflurbil.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Ethenzamide.Experimental
Ethyl biscoumacetateTarenflurbil may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Evening primrose oil.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Tarenflurbil.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Feprazone.Experimental
Ferulic acidTarenflurbil may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Tarenflurbil.Approved, Investigational
FleroxacinTarenflurbil may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Tarenflurbil.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Fludrocortisone.Approved, Investigational
FluindioneTarenflurbil may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineTarenflurbil may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Tarenflurbil.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Flurbiprofen.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Fluticasone furoate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Tarenflurbil.Approved, Nutraceutical, Vet Approved
FondaparinuxTarenflurbil may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Tarenflurbil.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Formestane.Approved, Investigational, Withdrawn
FramycetinTarenflurbil may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
GabexateTarenflurbil may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinTarenflurbil may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinTarenflurbil may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Tarenflurbil.Approved, Withdrawn
GemifloxacinTarenflurbil may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinTarenflurbil may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinTarenflurbil may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ATarenflurbil may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GinsengThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Ginseng.Approved, Investigational, Nutraceutical
GrepafloxacinTarenflurbil may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Tarenflurbil is combined with HE3286.Investigational
HeparinTarenflurbil may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Higenamine.Investigational
HydralazineTarenflurbil may decrease the antihypertensive activities of Hydralazine.Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Tarenflurbil.Approved, Investigational
Hygromycin BTarenflurbil may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbuproxamThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Icatibant.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Icosapent.Approved, Nutraceutical
IdraparinuxTarenflurbil may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tarenflurbil.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tarenflurbil.Approved
IndenololTarenflurbil may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Indoprofen.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tarenflurbil.Approved, Investigational
IsepamicinTarenflurbil may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Istaroxime.Investigational
KanamycinTarenflurbil may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Ketoprofen.Approved, Vet Approved
LandiololTarenflurbil may decrease the antihypertensive activities of Landiolol.Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Tarenflurbil.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Tarenflurbil.Approved, Investigational
LepirudinTarenflurbil may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanTarenflurbil may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololTarenflurbil may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololTarenflurbil may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinTarenflurbil may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Tarenflurbil.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Lisofylline.Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Tarenflurbil.Experimental
LomefloxacinTarenflurbil may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Lornoxicam.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Tarenflurbil.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Tarenflurbil.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tarenflurbil.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Tarenflurbil is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Mefenamic acid.Approved
MelagatranTarenflurbil may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Meloxicam.Approved, Vet Approved
MepindololTarenflurbil may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Tarenflurbil.Approved, Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Tarenflurbil.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tarenflurbil.Approved
MetipranololTarenflurbil may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tarenflurbil.Approved
MicronomicinTarenflurbil may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Tarenflurbil.Approved, Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Tarenflurbil.Approved
MizoribineThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Tarenflurbil.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Tarenflurbil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tarenflurbil.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Nabumetone.Approved
NadololTarenflurbil may decrease the antihypertensive activities of Nadolol.Approved
NadroparinTarenflurbil may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatTarenflurbil may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Tarenflurbil.Approved
Nalidixic AcidTarenflurbil may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Tarenflurbil is combined with NCX 1022.Investigational
NeamineTarenflurbil may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololTarenflurbil may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinTarenflurbil may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NepafenacThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Nepafenac.Approved, Investigational
NetilmicinTarenflurbil may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Niflumic Acid.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Nitroaspirin.Investigational
NorfloxacinTarenflurbil may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinTarenflurbil may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tarenflurbil.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tarenflurbil.Approved
OlsalazineTarenflurbil may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Tarenflurbil is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Orgotein.Vet Approved
OtamixabanTarenflurbil may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Oxaprozin.Approved
Oxolinic acidTarenflurbil may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololTarenflurbil may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tarenflurbil.Approved, Withdrawn
PalmidrolThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Palmidrol.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Parecoxib.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Parthenolide.Approved, Investigational
PazufloxacinTarenflurbil may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinTarenflurbil may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololTarenflurbil may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateTarenflurbil may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateTarenflurbil may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Perindopril.Approved
PhenindioneTarenflurbil may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonTarenflurbil may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tarenflurbil.Approved, Investigational
PindololTarenflurbil may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidTarenflurbil may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Tarenflurbil.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Tarenflurbil.Approved, Investigational
Piromidic acidTarenflurbil may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorTarenflurbil may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinTarenflurbil may decrease the excretion rate of Plazomicin which could result in a higher serum level.Approved, Investigational
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Tarenflurbil.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Pomalidomide.Approved
Potassium CitrateTarenflurbil may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololTarenflurbil may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Tarenflurbil.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Prednicarbate.Approved, Investigational
PrednisoneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Tarenflurbil can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Propacetamol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Tarenflurbil.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Tarenflurbil.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Tarenflurbil.Vet Approved
Protein CTarenflurbil may increase the anticoagulant activities of Protein C.Approved
Protein S humanTarenflurbil may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeTarenflurbil may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinTarenflurbil may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Tarenflurbil.Investigational
PuromycinTarenflurbil may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Tarenflurbil.Approved
RamiprilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinTarenflurbil may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinTarenflurbil may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Risedronate.Approved, Investigational
RivaroxabanTarenflurbil may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Rofecoxib.Approved, Investigational, Withdrawn
RosoxacinTarenflurbil may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinTarenflurbil may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Tarenflurbil.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Salicylamide.Approved
SalsalateThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tarenflurbil.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Tarenflurbil.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Tarenflurbil.Approved, Investigational
SeliciclibThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Serrapeptase.Investigational
SisomicinTarenflurbil may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinTarenflurbil may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
SotalolTarenflurbil may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinTarenflurbil may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Spirapril.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Tarenflurbil.Investigational
StreptomycinTarenflurbil may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulodexideTarenflurbil may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Tarenflurbil.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Suxibuzone.Experimental
TacrolimusTarenflurbil may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Tarenflurbil.Approved
TalinololTarenflurbil may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Tarenflurbil.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Tarenflurbil.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tarenflurbil.Approved, Investigational
TemafloxacinTarenflurbil may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Tepoxalin.Vet Approved
TerbutalineTarenflurbil may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Teriflunomide.Approved
TertatololTarenflurbil may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Tiaprofenic acid.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololTarenflurbil may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Tixocortol.Approved, Withdrawn
TobramycinTarenflurbil may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Tolmetin.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Tarenflurbil.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Trandolapril.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tarenflurbil.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tarenflurbil.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Triamcinolone.Approved, Vet Approved
TriamtereneTarenflurbil may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Tarenflurbil.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Triptolide.Investigational
TrovafloxacinTarenflurbil may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinTarenflurbil may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Tarenflurbil.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Tarenflurbil.Approved, Investigational
WarfarinTarenflurbil may increase the anticoagulant activities of Warfarin.Approved
XimelagatranTarenflurbil may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Zaltoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Tarenflurbil.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tarenflurbil.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
92337
PubChem Substance
175426967
ChemSpider
83361
BindingDB
50172473
ChEBI
38666
ChEMBL
CHEMBL190083
HET
FLR
Wikipedia
Tarenflurbil
PDB Entries
3r94 / 3rr3

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers1
2Unknown StatusTreatmentProstate Cancer1
3CompletedTreatmentAlzheimer's Disease (AD) / Dementias1
3TerminatedTreatmentAlzheimer's Disease (AD)1
3TerminatedTreatmentAlzheimer's Disease (AD) / Dementias1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0249 mg/mLALOGPS
logP3.57ALOGPS
logP3.94ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)4.42ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area37.3 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity67.29 m3·mol-1ChemAxon
Polarizability25.31 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9824
Caco-2 permeable+0.8866
P-glycoprotein substrateNon-substrate0.76
P-glycoprotein inhibitor INon-inhibitor0.9061
P-glycoprotein inhibitor IINon-inhibitor0.9739
Renal organic cation transporterNon-inhibitor0.912
CYP450 2C9 substrateNon-substrate0.7247
CYP450 2D6 substrateNon-substrate0.9249
CYP450 3A4 substrateNon-substrate0.7205
CYP450 1A2 substrateInhibitor0.8663
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.9546
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9674
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8752
Ames testNon AMES toxic0.9659
CarcinogenicityNon-carcinogens0.5554
BiodegradationNot ready biodegradable0.9861
Rat acute toxicity3.1121 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9849
hERG inhibition (predictor II)Non-inhibitor0.9116
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-002b-1910000000-0371815b89a4378bec81

Taxonomy

Description
This compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Biphenyls and derivatives
Direct Parent
Biphenyls and derivatives
Alternative Parents
Phenylpropanoic acids / Monocyclic monoterpenoids / Aromatic monoterpenoids / Fluorobenzenes / Aryl fluorides / Monocarboxylic acids and derivatives / Carboxylic acids / Organofluorides / Organic oxides / Hydrocarbon derivatives
show 1 more
Substituents
Biphenyl / 2-phenylpropanoic-acid / P-cymene / Aromatic monoterpenoid / Monocyclic monoterpenoid / Monoterpenoid / Fluorobenzene / Halobenzene / Aryl halide / Aryl fluoride
show 11 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
flurbiprofen (CHEBI:38666)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Ubiquitin protein ligase binding
Specific Function
Regulatory subunit of the IKK core complex which phosphorylates inhibitors of NF-kappa-B thus leading to the dissociation of the inhibitor/NF-kappa-B complex and ultimately the degradation of the i...
Gene Name
IKBKG
Uniprot ID
Q9Y6K9
Uniprot Name
NF-kappa-B essential modulator
Molecular Weight
48197.35 Da

Drug created on November 18, 2007 11:23 / Updated on August 02, 2018 05:30